Immunomedics Inc - Company Profile
Powered by 
All the data and insights you need on Immunomedics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Immunomedics Inc Strategy Report
- Understand Immunomedics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Immunomedics Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| CN109562172B | Grant | 抗HLA-DR抗体药物缀合物IMMU-140(hL243-CL2A-SN-38)在HLA-DR阳性癌症中的功效 | A61K47/6803; A61K47/6849; A61P35/02; A61P35/04; C07K16/2833 | August 16, 2022 |
| EP4035689A1 | Application | DOSIERUNGEN VON IMMUNKONJUGATEN VON ANTIKÖRPERN UND SN-38 FÜR VERBESSERTE WIRKSAMKEIT UND REDUZIERTE TOXIZITÄT | A61B6/481; A61K2039/505; A61K2039/507; A61K2039/545; A61K2039/55; A61K31/337; A61K31/4184; A61K31/437; A61K31/4375; A61K31/454; A61K31/4745; A61K31/513; A61K31/675; A61K31/7088; A61K31/713; A61K45/06; A61K47/68; A61K47/6803; A61K47/6851; A61K47/6853; A61P35/00; A61P35/02; A61P35/04; C07K16/2803; C07K16/2833; C07K16/2887; C07K16/30; C07K16/3007; C07K16/3015; C07K16/3023; C07K16/303; C07K16/3061; C07K16/3092; C07K16/32; C07K2317/24; C07K2317/73; C07K2317/77; C07K2317/92; C07K2317/94 | August 03, 2022 |
| CN114796501A | Application | 抗体与治疗剂的组合治疗癌症的方法 | A61K2039/505; A61K2039/545; A61K31/337; A61K31/357; A61K31/502; A61K31/519; A61K31/52; A61K39/395; A61K39/39558; A61K45/06; A61K47/6803; A61K47/6849; A61K47/6851; A61K47/6853; A61P35/00; A61P35/02; A61P35/04; A61P43/00; C07K16/2803; C07K16/2887; C07K16/30; C07K16/3007; C07K2317/24; C07K2317/73; C07K2317/732; C07K2317/94 | July 29, 2022 |
| CN114796500A | Application | 组合抗TROP-2抗体与微管抑制剂、PARP抑制剂使癌症治疗结果显著改善 | A61K2039/505; A61K2039/545; A61K31/337; A61K31/357; A61K31/502; A61K31/519; A61K31/52; A61K39/395; A61K39/39558; A61K45/06; A61K47/6803; A61K47/6849; A61K47/6851; A61K47/6853; A61P35/00; A61P35/02; A61P35/04; A61P43/00; C07K16/2803; C07K16/2887; C07K16/30; C07K16/3007; C07K2317/24; C07K2317/73; C07K2317/732; C07K2317/94 | July 29, 2022 |
| HUE057977T2 | Application | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | A61B6/481; A61K2039/505; A61K2039/507; A61K2039/545; A61K2039/55; A61K31/337; A61K31/4184; A61K31/437; A61K31/4375; A61K31/454; A61K31/4745; A61K31/513; A61K31/675; A61K31/7088; A61K31/713; A61K45/06; A61K47/68; A61K47/6803; A61K47/6851; A61K47/6853; A61P35/00; A61P35/02; A61P35/04; C07K16/2803; C07K16/2833; C07K16/2887; C07K16/30; C07K16/3007; C07K16/3015; C07K16/3023; C07K16/303; C07K16/3061; C07K16/3092; C07K16/32; C07K2317/24; C07K2317/73; C07K2317/77; C07K2317/92; C07K2317/94 | June 28, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer